Compare Abbott Laboratories (ABT) vs Veritone Inc (VERI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Veritone Inc — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Veritone Inc trades at $1.19 (market cap $116.19M). The key difference: Abbott Laboratories is far larger — about 1436.8× Veritone Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| ABT | VERI | |
|---|---|---|
Market Cap | $166.94B | $116.19M |
Sector | Health | Technology |
52-Week High | $136.62 | $8.39 |
52-Week Low | $82.57 | $1.26 |
Enterprise Value | $193.69B | $148.22M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Veritone (VERI) trades at $1.36, up 3.82% on the day, but remains under significant pressure with a bearish technical signal and negative profitability. The company reported a net loss of $111.73 million in 2025, with a net income margin of -123.76%, while revenue declined slightly to $90 million in 2026. Multiple class-action lawsuits filed in July 2026 allege securities fraud related to improper revenue accounting, creating substantial legal overhangs.
The outlook is highly speculative; while the consensus price target of $5.25 implies significant upside, the stock faces severe fundamental challenges and legal risks. Investment opportunity hinges on successful business turnaround and resolution of litigation, but current financial performance and negative cash flow from operations present substantial downside risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
